Physician

Adam Hines, M.D.

According to 2025 Medicare claims, Adam Hines, M.D. (NPI: 1124472873) practices hematology/oncology in the Nassau County-Suffolk County, NY market, with the plurality of this provider's patient population coming from Nassau, NY. This provider's primary affiliated billing organization is NORTH SHORE HEMATOLOGY ONCOLOGY ASSOCIATES PC (NPI: 1396794574; TIN: 112419534) and primary practice location at 11570-4129. Hines is affiliated with the NewYork Quality Care (ACO ID: A2571), ilumed, LLC (ACO ID: D0005), and Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under both the MSSP and REACH models.

Hines' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 636 traditional Medicare patients, billed 56,826 HCPCS/CPT codes, and received $880,199 in Medicare payments. The top billing code was 99233 (Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes). Part D data shows 800 prescription claims across 118 beneficiaries totaling $2,350,092 in drug costs, led by Darzalex Faspro (Daratumumab-Hyaluronidase-Fihj). 2022 DME data shows 12 claims. Open Payments data shows 1 records totaling $120. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have risen steadily, from $2,889 to $2,350,092. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	65	197	$17,407
2020	137	378	$34,545
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	376	46,031	$547,690
2024	636	56,826	$880,199

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	12	30	$2,889
2017	48	138	$5,364
2018	12	32	$2,554
2019	14	44	$1,736
2020	11	24	$5,365
2021	N/R	N/R	N/R
2022	33	67	$205,008
2023	54	198	$1,264,199
2024	118	800	$2,350,092

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	26	$938
2021	N/R	12	$650
2022	N/R	12	$696
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	294	863	$103
80053	Blood test, comprehensive group of blood chemicals	252	550	$10
36415	Insertion of needle into vein for collection of blood sample	310	747	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	303	723	$8
83615	Lactate dehydrogenase (enzyme) level	199	405	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Darzalex Faspro	Daratumumab-Hyaluronidase-Fihj	43	1,204	$623,754
Jaypirca	Pirtobrutinib	11	330	$247,398
Aranesp	Darbepoetin Alfa In Polysorbat	60	1,470	$157,470
Perjeta	Pertuzumab	18	364	$135,623
Revlimid	Lenalidomide	11	238	$134,908

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$120	Boehringer Ingelheim Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adam Hines, M.D.?

Tedicare shows public-source Medicare data for Adam Hines, M.D. (NPI 1124472873), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam Hines, M.D. have ACO affiliation data?

Adam Hines, M.D. is shown with ACO affiliation data for NewYork Quality Care (MSSP, ACO ID A2571), ilumed, LLC (REACH, ACO ID D0005), and Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Adam Hines, M.D.?

Adam Hines, M.D. is linked to NORTH SHORE HEMATOLOGY ONCOLOGY ASSOCIATES PC (billing NPI 1396794574) in the available physician profile data.

Does Adam Hines, M.D. have Open Payments data?

Adam Hines, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.